Disclaimer: The Views/Opinions expressed and/or opinions provided in Videos and other content on MedEnrich Website are those of respective speakers. They do not purport to reflect the opinion or views of Dr.Reddy’s Laboratories Limited or its affiliates (collectively Dr.Reddy’s)in any manner whatsoever and accordingly ,Dr.Reddys does not recommend , endorse or make any representation about the veracity and appropriateness of the views ,opinions/ information on MedEnrich website. Content on MedEnrich website may discuss uses and dosage for therapeutic product that may not have been approved in by the relevant regulatory agencies in your country. Dr.Reddy’s does not support , endorse or encourage any off-label use. Please refer to approved label before prescribing.
Are we ready to consider tissue agnostic treatment options in Solid Tumors
Oncology Published 1 year ago
Content
Oncology
13m 52s
Guidelines for Treatment of Diffuse Gliomas
Published 15 Sep 2022
Classification & treatment of Gliomas have evolved from erstwhile histopathology based to recent one incorporating molecular markers. EANO (European Association of Neuro Oncology) 2021 guidelines key pathology recommendations include incorporation of immunohistochemistry for IDH R132H & ATRX protein, MGMT promoter methylation status for elderly glioma patients. Key recommendations for surgery include emphasis on obtaining complete resection across glioma entities. General recommendations include KPS & Neurological function assessment, MRI being preferred diagnostic imaging modality with or without contrast agent. Guidelines also highlight importance of obtaining tissue diagnosis in addition to MRI. Guidelines provide grade-based treatment algorithm IDH Mutant & Wild type Gliomas.
